Mustang Bio (MBIO) Earnings Analysis

Mustang Bio (MBIO) next reports earnings on 2026-08-18, consensus EPS -145.5 USD. Last quarter (2026-03-19) it beat with EPS -0.08 USD vs -5.5 USD est (+98.5%). It has beaten estimates in 2/3 recent quarters (67%). Trailing P/E -1.41.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does MBIO next report earnings?

Next earnings date2026-08-18
Consensus EPS estimate-145.5 USD
Revenue estimaten/a

MBIO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-19-0.08 USD-5.5 USD+98.5%Beat
2025-11-07-0.07 USDn/an/an/a
2025-08-08-0.19 USDn/an/an/a
2025-05-14-0.05 USDn/an/an/a
2025-03-24-37.95 USD-5.5 USD-590%Miss
2024-11-08-2 USD-6.5 USD+69.2%Beat

Beat rate: 2/3 (67%) over reported quarters with consensus data.

MBIO valuation and analyst view

Trailing P/E-1.41
Trailing EPS-0.40461 USD
Price / book0.46
Dividend yield0.00%
Market cap0.00B
Analyst consensusBuy (7 buy / 0 hold / 0 sell)

Related research pages

Frequently asked questions

When is Mustang Bio (MBIO)'s next earnings date?

Mustang Bio is next scheduled to report on 2026-08-18, with a consensus EPS estimate of -145.5 USD.

Did MBIO beat earnings last quarter?

In its 2026-03-19 report, MBIO posted EPS of -0.08 USD versus a -5.5 USD estimate — a beat of 98.5%.

What is MBIO's earnings track record?

Over the last 3 reported quarters with consensus data, MBIO beat estimates 2 times (67%).

What is MBIO's current P/E ratio and EPS?

MBIO trades at a trailing P/E of -1.41 on trailing EPS of -0.4046149582717607 USD.

What do analysts rate MBIO?

Analyst consensus is "Buy" across 7 ratings (0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell).